Prostate cancer is the most common cancer in men in the UK with more than 35,000 people diagnosed every year. A third of those with the disease will die from it. The University is at the forefront of treatment development in prostate cancer, undertaking clinical trials in new approaches such as gene therapy.
Our researchers, in collaboration with surgeons at the Queen Elizabeth Hospital, are undertaking an exciting new clinical trial using a combination of thermotherapy and immunotherapy.
HIFU is a treatment that is delivered in a day clinic for men with early prostate cancer. The immunostimulants have been shown to benefit patients with advanced prostate cancer. There is a lot of very encouraging evidence that these two treatments will work better in combination.
We will recruit 20 men to the trial, who have progressing prostate cancer, and for whom standard treatment has failed. The results will help us to see if the technique of combining HIFU with immunostimulants is effective against prostate cancer. This could in turn lead us to a larger trial.
This therapeutic approach offers the hope of symptom relief and improved life expectancy to hundreds of thousands of prostate cancer patients worldwide who are suffering from progression of their disease. We believe this treatment could extend life by between six and 12 months in men who have run out of other treatment options.
One thousand supporters giving £4 could fund one patient's treatment
If 200 supporters made a gift of £100, five patients could go through the trial
If 80 donors gave £1,000 we could fund the entire trial
Donate online or text CIRC05 plus your chosen amount to 70070 to give today.